Core Viewpoint - Bragar Eagel & Squire, P.C. is investigating potential claims against Tempus AI, Inc. following a class action complaint that alleges breaches of fiduciary duties by the company's board of directors during the specified class period [1][2]. Group 1: Allegations and Issues - The complaint alleges that Tempus inflated the value of contract agreements, many of which were with related parties and included non-binding opt-ins or were self-funded [2]. - Concerns were raised regarding the credibility of Tempus' joint venture with SoftBank, suggesting it appeared to involve "round-tripping" capital to create revenue [2]. - The business model of Tempus-acquired Ambry is criticized for aggressive and potentially unethical billing practices, risking scrutiny and sustainability [2]. - AstraZeneca reportedly reduced its financial commitments to Tempus through a questionable "pass-through payment" arrangement [2]. - These issues collectively indicate weaknesses in Tempus' core operations and revenue prospects [2]. Group 2: Financial Impact - Following the release of a report by Spruce Point Capital Management that raised significant concerns about Tempus' management and financial reporting, the stock price of Tempus fell by $12.67 per share, or 19.23%, from $65.87 to $53.20 on May 28, 2025 [3][4]. Group 3: Legal and Contact Information - Long-term stockholders of Tempus are encouraged to contact Bragar Eagel & Squire for discussions regarding their legal rights and potential claims [1][5]. - The law firm specializes in representing individual and institutional investors in complex litigation across various courts [6].

Core Viewpoint - Bragar Eagel & Squire, P.C. is investigating potential claims against West Pharmaceutical Services, Inc. due to allegations of fiduciary duty breaches by the board of directors following a class action complaint filed on June 20, 2025 [1] Company Overview - West Pharmaceutical Services, Inc. is a medical supplies company based in Exton, Pennsylvania, serving as a key supplier to the pharmaceutical, biotechnology, and generic drug industries [2] Allegations and Issues - The class action complaint alleges that West failed to disclose significant destocking issues in its high-margin High-Value Products portfolio, despite claiming strong visibility into customer demand [2] - The SmartDose device, positioned as a high-margin growth product, was found to be dilutive to profit margins due to operational inefficiencies [2] - Margin pressures raised the risk of costly restructuring activities, including the exit from continuous glucose monitoring contracts with long-standing customers [2] - Positive statements made by the company regarding its business and prospects were claimed to be materially false or misleading [2] Disclosure of Financial Issues - The truth about the alleged fraud was revealed on February 13, 2025, when West issued weak revenue and earnings forecasts for 2025, attributing the disappointing guidance to contract manufacturing headwinds and the loss of two major customers [3] - West indicated that its SmartDose devices would be margin-dilutive in 2025 and mentioned plans to improve the device's economics [3] - Following this disclosure, West's stock price dropped by $123.17 per share, a decline of 38%, closing at $199.11 on February 13, 2025 [3]